DB:65H

Stock Analysis Report

HTG Molecular Diagnostics

Executive Summary

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine.


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has HTG Molecular Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 65H's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.9%

65H

1.0%

DE Healthcare Services

0.2%

DE Market


1 Year Return

-75.3%

65H

24.7%

DE Healthcare Services

14.4%

DE Market

Return vs Industry: 65H underperformed the German Healthcare Services industry which returned 24.7% over the past year.

Return vs Market: 65H underperformed the German Market which returned 14.4% over the past year.


Shareholder returns

65HIndustryMarket
7 Day-0.9%1.0%0.2%
30 Day-7.0%4.0%0.9%
90 Day-14.4%10.3%4.6%
1 Year-75.3%-75.3%25.8%24.7%17.9%14.4%
3 Yearn/a73.5%69.0%15.7%5.6%
5 Yearn/a150.4%139.3%23.4%6.5%

Price Volatility Vs. Market

How volatile is HTG Molecular Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is HTG Molecular Diagnostics undervalued compared to its fair value and its price relative to the market?

1.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 65H's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 65H's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 65H is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: 65H is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 65H's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 65H is good value based on its PB Ratio (1.2x) compared to the DE Healthcare Services industry average (3.2x).


Next Steps

Future Growth

How is HTG Molecular Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

3.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 65H is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 65H is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 65H is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 65H's revenue (18.6% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: 65H's revenue (18.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 65H's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has HTG Molecular Diagnostics performed over the past 5 years?

4.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 65H is currently unprofitable.

Growing Profit Margin: 65H is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 65H is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare 65H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 65H is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (5.9%).


Return on Equity

High ROE: 65H has a negative Return on Equity (-60.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is HTG Molecular Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: 65H's short term assets ($43.9M) exceed its short term liabilities ($8.4M).

Long Term Liabilities: 65H's short term assets ($43.9M) exceed its long term liabilities ($14.4M).


Debt to Equity History and Analysis

Debt Level: 65H's debt to equity ratio (34.9%) is considered satisfactory.

Reducing Debt: 65H had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: 65H has a low level of unsold assets or inventory.

Debt Coverage by Assets: 65H's debt is covered by short term assets (assets are 4.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 65H has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 65H has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -1.9% each year.


Next Steps

Dividend

What is HTG Molecular Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 65H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 65H's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 65H's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 65H's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 65H's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

John Lubniewski (55yo)

0.8yrs

Tenure

US$1,297,753

Compensation

Mr. John L. Lubniewski serves as Director at HTG Molecular Diagnostics, Inc. since April 2019. Mr. Lubniewski serves as President since April 2018 and served as Chief Operating Officer at HTG Molecular Dia ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD1.30M) is above average for companies of similar size in the German market ($USD412.57K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Johnson
Executive Chairman0.9yrsUS$2.01m0.44% $140.5k
John Lubniewski
President0.8yrsUS$1.30m0.27% $88.0k
Shaun McMeans
Senior VP of Finance & Administration8yrsUS$1.04m0.20% $64.3k
Laura Godlewski
Principal Accounting Officer0.8yrsno data0.028% $9.1k
Maureen Cronin
Senior VP & Chief Scientific Officer1.3yrsno datano data
Debra Gordon
Senior VP & Chief Legal Counsel8.7yrsUS$296.70kno data
Sam Rua
Senior Vice President of Regulatory Affairs & Quality Systems2yrsno datano data
Patrick Roche
Senior Vice President of Research & Development5.8yrsUS$507.38k0.075% $24.0k
Byron Lawson
Senior Vice President0yrsno data0.075% $24.0k
Laura Beggrow
President of Diagnostics0yrsno datano data

1.6yrs

Average Tenure

58.5yo

Average Age

Experienced Management: 65H's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Timothy Johnson
Executive Chairman0.9yrsUS$2.01m0.44% $140.5k
John Lubniewski
President0.8yrsUS$1.30m0.27% $88.0k
Harry George
Independent Director18.1yrsUS$83.88k0.067% $21.5k
Michelle Griffin
Independent Director1.5yrsUS$84.95k0.0043% $1.4k
Lee McCracken
Independent Director4.3yrsUS$85.13k0.0086% $2.8k
Ann Hanham
Lead Independent Director0.9yrsUS$113.88k0.013% $4.0k
Donnie Hardison
Independent Director3.8yrsUS$86.38k0.022% $6.9k
James LaFrance
Independent Director4.2yrsUS$92.63k0.022% $6.9k
Fred Hirsch
Member of Scientific Advisory Board4yrsno datano data
James Gulley
Member of Scientific Advisory Board4yrsno datano data

3.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 65H's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.9%.


Top Shareholders

Company Information

HTG Molecular Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: HTG Molecular Diagnostics, Inc.
  • Ticker: 65H
  • Exchange: DB
  • Founded: 1997
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$34.570m
  • Listing Market Cap: US$32.022m
  • Shares outstanding: 58.04m
  • Website: https://www.htgmolecular.com

Number of Employees


Location

  • HTG Molecular Diagnostics, Inc.
  • 3430 East Global Loop
  • Tucson
  • Arizona
  • 85706
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HTGMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2015
65HDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2015

Biography

HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company’s assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 23:24
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.